Navigation Links
Gentium's Defibrotide Highlighted in Two Poster Presentations at,American Association for Cancer Research Annual Meeting

Commenting on these pre-clinical results, Dr. Eissner stated, "Our in vivo and in vitro data suggest that while Defibrotide is known for its anti-inflammatory and endothelium-protecting function, it also inhibits (tumor) blood vessel formation. This concept is supported by RT-PCR data showing that Defibrotide significantly down-regulates heparanase expression in endothelial and tumor cells, and thus should be considered for further testing as an anticancer agent."

Laura Ferro, M.D., Gentium's president and chief executive officer, said, "These pre-clinical results are very encouraging and continue to expand our scientific knowledge of Defibrotide's multi-factorial mechanisms of action and help us to better understand its therapeutic value as a potentially powerful anticancer agent.

"We are especially pleased with the data presented at AACR as it further elucidates Defibrotide's mechanism of action and corroborates positive preliminary data from an independent Phase I/II study of Defibrotide to treat multiple myeloma in combination with melphalan, prednisone and thalidomide underway in Italy."

About Gentium

Gentium, S.p.A., located in Como, Italy, is a biopharmaceutical company focused on the research, discovery and development of drugs to treat and prevent a variety of vascular diseases and conditions related to cancer and cancer treatments. Defibrotide, the Company's lead product candidate, is an investigational drug that has been granted Orphan Drug status and Fast Track Designation by the U.S. Food and Drug Administration to treat Severe Veno-occlusive disease (VOD) and Orphan Medicinal Product Designation by the European Commission both to treat and to prevent VOD.

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements." In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expect," "plan," "anticipate,
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Gentiums Defibrotide Seen as Active in Multiple Myeloma
2. Gentiums Defibrotide Highlighted in Poster Presentation at World Congress of Nephrology
3. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
4. Isotechnikas Lead Drug, ISA247, To Be Highlighted at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
5. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
6. Alfacells Onconase Highlighted in Latest Edition of Handbook of Therapeutic Antibodies
7. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
8. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
9. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
10. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
11. Savient Pharmaceuticals Announces Acceptance of Two Gout-Related Abstracts for Poster Presentation at the European League Against Rheumatism (EULAR) 2007 Annual Congress
Post Your Comments:
(Date:12/24/2014)... Echo Therapeutics, Inc. (NASDAQ: ... skin permeation, continuous glucose monitoring and associated technologies, ... has been appointed Chief Executive Officer effective December ... years of experience in the medical device, pharmaceutical ... as Vice President, Business Development, Otsuka Pharmaceuticals as well ...
(Date:12/24/2014)... , Dec. 23, 2014   Synageva ... a biopharmaceutical company developing therapeutic products for rare ... Agency (EMA) of the Marketing Authorization Application (MAA) ... recently granted the company,s request for accelerated assessment, ... regulatory review time.   The MAA, ...
(Date:12/24/2014)... 2014 Tianyin Pharmaceutical Co., Inc. (NYSE ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded ... that the Company achieved the Public Notice (Gong ... certificate of TPI,s Qionglai Facility (QLF) from the ... notice period is a significant procedure of GMP ...
Breaking Medicine Technology:Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3
... Major Lupin Limited announced today that its U.S. subsidiary, ... Award by the Healthcare Distribution Management Association (HDMA) for ... with sales of up to $100 million in the ... winners are selected by HDMA Distributor members to recognize ...
... Laboratories, a leading provider of medication monitoring services to ... hiring of Martin Price as General Counsel and Janna ... Officer. As Millennium Laboratories General Counsel, Mr. ... Howard Appel , Millennium Laboratories, President, said, "We ...
Cached Medicine Technology:HDMA Honors Lupin with DIANA Award for Best Overall Generic Manufacturer 2HDMA Honors Lupin with DIANA Award for Best Overall Generic Manufacturer 3Millennium Laboratories Announces New General Counsel Martin Price and Chief Compliance Officer Janna Sipes 2Millennium Laboratories Announces New General Counsel Martin Price and Chief Compliance Officer Janna Sipes 3
(Date:12/26/2014)... CA (PRWEB) December 26, 2014 ... score of 3.1 out of 5. This score reflects ... low level of product specialization, low switching costs and ... is reduced by the low availability of substitutes for ... world price of steel and aluminum, key inputs in ...
(Date:12/26/2014)... December 26, 2014 Plugin and template developers ... Volume 5 Plugin for Final Cut Pro X. , “TransPack ... light tool to pull off an industry professional look” Said ... their hands on TransPack Volume 5, a new level of ... a set of over 50 Final Cut Pro X transitions ...
(Date:12/26/2014)... Philadelphia, PA (PRWEB) December 26, 2014 ... to Work in the state of Pennsylvania for 2014. ... the first statewide programs of its kind in the ... Pennsylvania Foundation, the Pennsylvania Department of Community and Economic ... Human Resource Management and the Central Penn Business Journal. ...
(Date:12/25/2014)... The microscopy market is estimated to grow at ... by 2019. Optical microscopy is the largest segment ... segment is expected to show the fastest growth ... nanotechnology, technological advancements, and increasing federal support to ... Full Copy of Report @ http://www.marketsandmarkets.com/Market-Reports/world-microscopy-399.html ...
(Date:12/25/2014)... TX (PRWEB) December 26, 2014 ... Market Analysis to 2023” focuses on the current ... opportunities in the colorectal cancer market. Stivarga is ... of colon or rectal cancer. Boehringer Ingelheim is ... for the treatment of refractory CRC in the ...
Breaking Medicine News(10 mins):Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Today a new plugin was announced from Pixel Film Studios, TransPack Volume 5 for Final Cut Pro X 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4
... Sept. 11 NBTY, Inc. (NYSE:,NTY) (http://www.NBTY.com ), ... announced that it will web cast the,presentation by Harvey ... CL King Best Ideas Conference in New York on ... be web cast live on NBTY,s web site, (http://www.nbty.com ...
... 11 If you,ve purchased prescription,drugs sometime ... receive some money as,part of a multi-million ... from the AWP Track 2 Settlement Administrator ... access video, audio, text, graphics and,photos for ...
... Black lung disease is not a problem of the ... die from it and associated ailments. , In response, ... R. Saylor, associate professor of mechanical engineering at Clemson ... reducing harmful particulate levels in coal mines. Saylor,s research ...
... Sept. 11 A US House Government,Oversight subcommittee ... a mandatory requirement, to reduce mercury emissions. The,Mercury ... at two,congressional hearings over the past several months ... Subcommittee report found that the best way to ...
... Sept. 11 Wolters Kluwer Health, a,division ... information and business,intelligence for students, professionals, and ... the pharmaceutical industry, announced,today the appointment of ... & Education Unit., Lubeck comes to ...
... docs, says researcher , , THURSDAY, Sept. 11 (HealthDay News) -- ... be the last place you would have a discussion about ... a conversation. , Almost half of those included in ... that prayer was very important to their sense of well-being, ...
Cached Medicine News:Health News:NBTY to Web Cast Presentation at CL King Best Ideas Conference 2Health News:CDC awards Clemson researcher $700,000 to study black lung prevention 2Health News:To Reduce Mercury Pollution, 'Dentists need a mandatory requirement,' According to US House Oversight Report; Mercury Group Concurs 2Health News:Wolters Kluwer Health Appoints Scott Lubeck Vice President, Technology of its Professional & Education Unit 2Health News:Spiritual Beliefs Part of Health Care for Some 2Health News:Spiritual Beliefs Part of Health Care for Some 3
Implantable medical grade silicone end cap for insulation and sealing protection of 5 mm or 3.2 mm connectors....
...
... Renewal 3 cardiac resynchronization therapy ... and cardiac resynchronization therapy. Features: ... and left ventricular (LV) pacing ... irregular ventricular intervals during conducted ...
... housing. MRI-compatible. Requires a guide sphere ... a standard 1.0 - 1.5 cm burr ... assembly with a white collar. MRI-compatible. ... Sterile; single-use only Guide sphere assembly with ...
Medicine Products: